Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 201-205

  Sack, David A ^a   Sack, R Bradley ^b   Shimko, Janet ^b   Gomes, George ^b   O'Sullivan, Donna ^b   Metcalfe, Karen ^b   Spriggs, Dale ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CHOLERA VACCINE; LIVE VACCINE; NEW DRUG; PLACEBO;

ADULT; ARTICLE; CHOLERA; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FECES LEVEL; DRUG SAFETY; FEMALE; FREEZE DRYING; HOSPITAL PATIENT; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0030904790     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514025     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. Update: Vibrio cholerae O1 - Western Hemisphere, 1991 - 1994, and V. cholerae O139 - Asia, 1994. JAMA 1995;273:1169.
2. Sack DA, Freij L, Holmgren J, eds. From the Swedish Agency for Research Cooperation with Developing Countries. Prospects for public health benefits in developing countries from new vaccines against enteric infections. J Infect Dis 1991;163:503-6.
3. World Health Organization. Development of vaccines against cholera and diarrhoea due to enterotoxigenic Escherichia coli: memorandum from a WHO meeting. Bull World Health Organ 1990;68:303-12.
4. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986;2:124-7.
5. Levine MM, Kaper JB, Herrington DA, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988;2:467-70.
6. Taylor DN, Killeen KP, Hack DC, et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994;170:1518-23.
7. Kenner JR, Coster TS, Taylor DN, et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 1995; 172:1126-9.
8. Pearson GD, Woods A, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Proc Natl Acad Sci USA 1993;90:3750-4.
9. Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 1996;272:1910-4.
10. Sack DA, Clemens JD, Huda S, et al. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 1991;164:407-11.
11. Cryz SJ Jr, Levine MM, Kaper JB, Furer E, Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 1990;8:577-80.
12. Lagos R, Avendano A, Prado V, et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun 1995;63:707-9.
13. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992; 60:4430-2.
14. Concha A, Giraldo A, Castaneda E, et al. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Bull Pan Am Health Organ 1995;29:312-21.
15. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit - whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988;158:372-7.
16. Svennerholm AM, Jertborn M, Gothefors L, Karim AM, Sack DA, Holmgren J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit - whole cell vaccine. J Infect Dis 1984;149:884-93.
17. Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun 1991;59:996-1001.
18. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae - specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun 1993;61:729-33.
19. Czerkinsky C, Quiding M, Eriksson K, et al. Induction of specific immunity at mucosal surfaces: prospects for vaccine development. Adv Exp Med Biol 1995;371B:1409-16.
20. Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol 1986;24: 203-9.